Pharmacometric models for improved therapeutic drug monitoring of ceftriaxone, posaconazole and infliximab KU Leuven
In clinical drug development, “one dose fits all” is a key objective. However, variability in exposure (E) and response (R) is common and can result in suboptimal treatment of individual patients. To hit a predefined E/R target in each patient, “therapeutic drug monitoring” or TDM is often implemented. TDM helps improving attainment of a desired E/R target by guiding individualised drug dosing based upon drug concentrations. “Population ...